Search

Your search keyword '"Roos S"' showing total 537 results
Start Over Author "Roos S" Language english
537 results on '"Roos S"'

1. Evaluation of a group-based online informed consent conversation (eConsent) in participants from a low-risk vaccination clinical trial

Author

Ngoc H. Tan, Melvin Lafeber, Roos S. G. Sablerolles, Isabelle Veerman Roders, Anna van de Hoef, Karenin van Grafhorst, Leo G. Visser, Douwe F. Postma, Abraham Goorhuis, Wim J. R. Rietdijk, and P. Hugo M. van der Kuy

Subjects
Group, eConsent, Informed consent, Medicine (General), R5-920
Abstract

Abstract Background Electronic informed consent (eConsent) usage has expanded in recent years in Europe, especially during the pandemic. Slow recruitment rate and limitations in participant outreach are the challenges often faced in clinical research. Given the benefits of eConsent and group counselling reported in the literature, group eConsent was implemented in recruitment for the SWITCH-ON study. We aim to explore the experience of participants who attended group eConsent for the SWITCH-ON study and evaluate its potential for future use. Methods SWITCH-ON study aims to analyse the immunogenicity of a healthy population following bivalent COVID-19 booster vaccination. Four hundred thirty-four healthcare workers aged 18–65 were successfully recruited and sent a questionnaire about their experience with group eConsent. Out of 399 completed questionnaires (response rate 92%), 39 participants did not join group eConsent. The remaining 360 responses were included in the final analysis. Quantitative and qualitative data were reported using descriptive statistical analysis and thematic analysis respectively. Results Participants found that group eConsent was an efficient method that it allowed them to hear each other’s questions and concerns and created a sense of togetherness. However, limited privacy, barriers to asking questions in a group, and peer pressure can limit the use of group eConsent. One hundred sixty-five (46%) participants thought that group eConsent was suitable to recruit participants with diseases or conditions, while 87 (24%) reported limitations with this method. The remaining participants suggested that applicability of group eConsent depended on the diseases or conditions of the study population, and one-to-one conversation should always be available. Participants who had experienced both one-to-one and group eConsent shared different preferred consent formats for future studies. Conclusion Group eConsent was positively evaluated by the participants of a low-risk vaccination study. Participants advised using webinars to provide general information about the study, followed by an individual session for each participant, would retain the benefits of group eConsent and minimise the limitations it posed. This proposed setting addresses privacy questions and makes group eConsent easier to implement. Trial registration ClinicalTrials.gov NCT05471440 (registered on 22nd of July, 2022).

Published
2024
Full Text
View/download PDF

2. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Author

Luca M. Zaeck, Ngoc H. Tan, Wim J. R. Rietdijk, Daryl Geers, Roos S. G. Sablerolles, Susanne Bogers, Laura L. A. van Dijk, Lennert Gommers, Leanne P. M. van Leeuwen, Sharona Rugebregt, Abraham Goorhuis, Douwe F. Postma, Leo G. Visser, Virgil A. S. H. Dalm, Melvin Lafeber, Neeltje A. Kootstra, Anke L. W. Huckriede, Bart L. Haagmans, Debbie van Baarle, Marion P. G. Koopmans, SWITCH-ON Research Group, P. Hugo M. van der Kuy, Corine H. GeurtsvanKessel, and Rory D. de Vries

Subjects
Science
Abstract

Abstract Waning antibody responses after COVID-19 vaccination combined with the emergence of the SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, bivalent mRNA-based booster vaccines encoding the ancestral spike protein in combination with that of Omicron BA.1 or BA.5 were introduced. Since then, different BA.2-descendent lineages have become dominant, such as XBB.1.5, JN.1, or EG.5.1. Here, we report post-hoc analyses of data from the SWITCH-ON study, assessing how different COVID-19 priming regimens affect the immunogenicity of bivalent booster vaccinations and breakthrough infections (NCT05471440). BA.1 and BA.5 bivalent vaccines boosted neutralizing antibodies and T-cells up to 3 months after boost; however, cross-neutralization of XBB.1.5 was poor. Interestingly, different combinations of prime-boost regimens induced divergent responses: participants primed with Ad26.COV2.S developed lower binding antibody levels after bivalent boost while neutralization and T-cell responses were similar to mRNA-based primed participants. In contrast, the breadth of neutralization was higher in mRNA-primed and bivalent BA.5 boosted participants. Combined, our data further support the current use of monovalent vaccines based on circulating strains when vaccinating risk groups, as recently recommended by the WHO. We emphasize the importance of the continuous assessment of immune responses targeting circulating variants to guide future COVID-19 vaccination policies.

Published
2024
Full Text
View/download PDF

3. The short- and longer-term effects of brief behavioral parent training versus care as usual in children with behavioral difficulties: study protocol for a randomized controlled trial

Author

Roos S. van Doornik, Saskia van der Oord, Joli Luijckx, Annabeth P. Groenman, Patty Leijten, Marjolein Luman, Pieter J. Hoekstra, Barbara J. van den Hoofdakker, and Tycho J. Dekkers

Subjects
Children, Behavioral difficulties, Brief, Behavioral parent training, Individually tailored, Psychosocial intervention, Psychiatry, RC435-571
Abstract

Abstract Background The access to and uptake of evidence-based behavioral parent training for children with behavioral difficulties (i.e., oppositional, defiant, aggressive, hyperactive, impulsive, and inattentive behavior) are currently limited because of a scarcity of certified therapists and long waiting lists. These problems are in part due to the long and sometimes perceived as rigid nature of most evidence-based programs and result in few families starting behavioral parent training and high dropout rates. Brief and individually tailored parenting interventions may reduce these problems and make behavioral parent training more accessible. This protocol paper describes a two-arm, multi-center, randomized controlled trial on the short- and longer-term effectiveness and cost-effectiveness of a brief, individually tailored behavioral parent training program for children with behavioral difficulties. Methods Parents of children aged 2–12 years referred to a child mental healthcare center are randomized to (i) three sessions of behavioral parent training with optional booster sessions or (ii) care as usual. To evaluate effectiveness, our primary outcome is the mean severity of five daily ratings by parents of four selected behavioral difficulties. Secondary outcomes include measures of parent and child behavior, well-being, and parent–child interaction. We explore whether child and parent characteristics moderate intervention effects. To evaluate cost-effectiveness, the use and costs of mental healthcare and utilities are measured. Finally, parents’ and therapists’ satisfaction with the brief program are explored. Measurements take place at baseline (T0), one week after the brief parent training, or eight weeks after baseline (in case of care as usual) (T1), and six months (T2) and twelve months (T3) after T1. Discussion The results of this trial could have meaningful societal implications for children with behavioral difficulties and their parents. If we find the brief behavioral parent training to be more (cost-)effective than care as usual, it could be used in clinical practice to make parent training more accessible. Trial registration The trial is prospectively registered at ClinicalTrials.gov (NCT05591820) on October 24th, 2022 and updated throughout the trial.

Published
2024
Full Text
View/download PDF

4. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol

Author

Ngoc H. Tan, Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis, Douwe F. Postma, Leo G. Visser, Susanne Bogers, Daryl Geers, Luca M. Zaeck, Marion P. G. Koopmans, Virgil A. S. H. Dalm, Neeltje A. Kootstra, Anke L. W. Huckriede, Debbie van Baarle, Melvin Lafeber, Corine H. GeurtsvanKessel, Rory D. de Vries, and Paul-Hugo Marie van der Kuy

Subjects
COVID-19, immune memory, mRNA vaccine, adenovirus-based vaccine, immune response, Immunologic diseases. Allergy, RC581-607
Abstract

Vaccination against coronavirus disease 2019 (COVID-19) has contributed greatly to providing protection against severe disease, thereby reducing hospital admissions and deaths. Several studies have reported reduction in vaccine effectiveness over time against the Omicron sub-lineages. However, the willingness to receive regular booster doses in the general population is declining. To determine the need for repeated booster vaccinations in healthy individuals and to aid policymakers in future public health interventions for COVID-19, we aim to gain insight into the immunogenicity of the additional bivalent booster vaccination in a representative sample of the healthy Dutch population. The SWITCH ON study was initiated to investigate three main topics: i) immunogenicity of bivalent vaccines after priming with adenovirus- or mRNA-based vaccines, ii) immunological recall responses and reactivity with relevant variants after booster vaccination, and iii) the necessity of booster vaccinations for the healthy population in the future.Clinical trial registrationhttps://clinicaltrials.gov/, identifier NCT05471440.

Published
2022
Full Text
View/download PDF

5. Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

Author

Roos S. G. Sablerolles, Abraham Goorhuis, Corine H. GeurtsvanKessel, Rory D. de Vries, Anke L. W. Huckriede, Marion P. G. Koopmans, Melvin Lafeber, Douwe F. Postma, Debbie van Baarle, Leo G. Visser, Virgil A. S. H. Dalm, Neeltje A. Kootstra, Wim J. R. Rietdijk, and P. Hugo M. van der Kuy

Subjects
SARS-CoV-2, COVID-19, Homologous vaccination regimen, Heterologous vaccine regimen, randomized clinical trial, Ad26.Cov2.S, Immunologic diseases. Allergy, RC581-607
Published
2021
Full Text
View/download PDF

6. Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET): an international, multicentre, retrospective, observational cohort study

Author

Roos S G Sablerolles, MD, Melvin Lafeber, MD, Janneke A L van Kempen, MD, Bob P A van de Loo, Msc, Eric Boersma, ProfPhD, Wim J R Rietdijk, PhD, Harmke A Polinder-Bos, MD, Simon P Mooijaart, MD, Hugo van der Kuy, ProfPharmD, Jorie Versmissen, MD, Miriam C Faes, MD, LA Agnoletto, J Aleman, S Andreassi, LM Andrews, L Ashfield, H Bell, AKB Bengaard, SB Berlinghini, KB Bini, ZB Bisoffi, KB Blum, E Boemaars, GB Boni, TM Bosch, BE Bosma, F Boutkourt, C Bufarini, A Bulsink, RC Cabuk, GC Callens, MC Candela, MC Canonici, EC Capone, IC Carmo, FC Caruso, PC Chessa, GC Cohet, I Cornelissen-Wesseling, KML Crommentuijn, FM de Stoppelaar, HAJM de Wit, DS Deben, LJJ Derijks, MDC Di Carlo, J Diepstraten, B Dilek, DMK Duchek-Mann, MM Ebbens, LJ Ellerbroek, M Ezinga, MF Falcao, FF Falcao, LF Fantini, HF Farinha, PMG Filius, NJ Fitzhugh, G Fleming, TF Forsthuber, GG Gambarelli, MG Gambera, CGY García Yubero, Z Getrouw, CN Ghazarian, N Goodfellow, MQG Gorgas, RG Grinta, K Guda, DH Haider, J Hanley, KH Heitzeneder, WL Hemminga, LC Hendriksen, DL Hilarius, FEF Hogenhuis, IC Hoogendoorn-de Graaf, MBH Houlind, MAH Huebler, KPGM Hurkens, PKC Janssen, E Jong, MHW Kappers, KFM Keijzers, MK Kemogni, EM Kemper, RA Kranenburg, LL Krens, JL G Le Grand, J Liang, S Lim, NL Lindner, EL Loche, AL Lubich, B Maat, CM Maesano, AM Maiworm, M Maragna, FM Marchesini, IM Martignoni, G M Martini, CM Masini, R Mc Menamin, DM Mendes, M Miarons, R Moorlag, MR Müller, FN Nagele, KN Nemec, GO Oka, AG Otten-Helmers, SP Pagliarino, FP Pappalardo, M Patel, PM Peverini, FP Pieraccini, EMP Platania, NPK Pons-Kerjean, LPH Portillo Horcajada, GR Rametta, JR Rijo, EE Roelofsen, E Roobol-Meuwese, LR Rossi, SAH Russel, Z Safipour, FS Salaffi, L Saleh, AMS Schimizzi, JMGA Schols, MS Schwap, MG Scott, EAM Slijfer, EMA Slob, JS Soares, MS Solano, F Sombogaard, GS Stemer, MT Tardella, PGJ ter Horst, RT Tessari, J Tournoy, RB van den Berg, L Van der Linden, PD van der Linden, SC van Dijk, RW Van Etten, IMM van Haelst, M van Heuckelum, HJM van Kan, C van Nieuwkoop, HAW van Onzenoort, P van Wijngaarden, JDJ Verdonk, Fv Verri, JAMC Verstijnen, MV Veyrier, EV Viegas, LE Visser, A Vos, MAM Vromen, PC Wierenga, DR Wong, CZ Zenico, and TZ Zuppini

Subjects
Geriatrics, RC952-954.6, Medicine
Abstract

Summary: Background: During the COVID-19 pandemic, the scarcity of resources has necessitated triage of critical care for patients with the disease. In patients aged 65 years and older, triage decisions are regularly based on degree of frailty measured by the Clinical Frailty Scale (CFS). However, the CFS could also be useful in patients younger than 65 years. We aimed to examine the association between CFS score and hospital mortality and between CFS score and admission to intensive care in adult patients of all ages with COVID-19 across Europe. Methods: This analysis was part of the COVID Medication (COMET) study, an international, multicentre, retrospective observational cohort study in 63 hospitals in 11 countries in Europe. Eligible patients were aged 18 years and older, had been admitted to hospital, and either tested positive by PCR for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or were judged to have a high clinical likelihood of having SARS-CoV-2 infection by the local COVID-19 expert team. CFS was used to assess level of frailty: fit (CFS1–3), mildly frail (CFS4–5), or frail (CFS6–9). The primary outcome was hospital mortality. The secondary outcome was admission to intensive care. Data were analysed using a multivariable binary logistic regression model adjusted for covariates (age, sex, number of drugs prescribed, and type of drug class as a proxy for comorbidities). Findings: Between March 30 and July 15, 2020, 2434 patients (median age 68 years [IQR 55–77]; 1480 [61%] men, 954 [30%] women) had CFS scores available and were included in the analyses. In the total sample and in patients aged 65 years and older, frail patients and mildly frail patients had a significantly higher risk of hospital mortality than fit patients (total sample: CFS6–9 vs CFS1–3 odds ratio [OR] 2·71 [95% CI 2·04–3·60], p

Published
2021
Full Text
View/download PDF

8. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Author

Zaeck, Luca M., Tan, Ngoc H., Rietdijk, Wim J. R., Geers, Daryl, Sablerolles, Roos S. G., Bogers, Susanne, van Dijk, Laura L. A., Gommers, Lennert, van Leeuwen, Leanne P. M., Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Dalm, Virgil A. S. H., Lafeber, Melvin, Kootstra, Neeltje A., Huckriede, Anke L. W., Haagmans, Bart L., van Baarle, Debbie, Koopmans, Marion P. G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.

Published
2024
Full Text
View/download PDF

10. Suture versus open mesh repair for small umbilical hernia: Results of a propensity-matched cohort study

Author

Antor, M., Beck, M., Barrat, C., Berney, C., Binot, D., Bousquet, J., Blazquez, D., Bonan, A., Cas, O., Champault-Fezais, A., Chastan, P., Chollet, J.-M., Cossa, J.-P., Dabrowski, A., Delaunay, T., Démaret, S., Drissi, F., Demian, H., Dubuisson, V., Dugue, T., Fromont, G., Gillion, J.-F., Jacquin, C., Jurczak, F., Khalil, H., Launay-Savary, M., Lepère, M., Lépront, D., Longeville, J.H., Le Toux, N., Loriau, J., Magne, E., Ngo, P., Oberlin, O., Passot, G., Pavis d’Escurac, X., Putinier, J.B., Renard, Y., Romain, B., Soler, M., Roos, S., Thillois, J.-M., Tiry, P., Vu, P., Verhaeghe, R., Warlaumont, M., Zaranis, C., Frey, Samuel, Beauvais, Adrien, Soler, Marc, Beck, Mathieu, Dugué, Timothée, Pavis d’Escurac, Xavier, Dabrowski, André, Jurczak, Florent, and Gillion, Jean-François

Published
2023
Full Text
View/download PDF

11. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial

Author

Tan, Ngoc H, Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, GeurtsvanKessel, Corine H, de Vries, Rory D, and van der Kuy, P Hugo M

Published
2023
Full Text
View/download PDF

14. Age Moderates the Effect of Obesity on Mortality Risk in Critically Ill Patients With COVID-19: A Nationwide Observational Cohort Study*

Author

den Uil, Corstiaan A., Termorshuizen, Fabian, Rietdijk, Wim J. R., Sablerolles, Roos S. G., van der Kuy, Hugo P. M., Haas, Lenneke E. M., van der Voort, Peter H. J., de Lange, Dylan W., Pickkers, Peter, de Keizer, Nicolette F., Arbous, M. S., Barnas, M. G. W., Boer, D. P., Bosman, R. J., Brunnekreef, G. B., de Bruin, M. Th., de Graaff, M. J., de Jong, R. M., de Meijer, A. R., de Ruijter, W., de Waal, R., Dijkhuizen, A., Dongelmans, D. A., Dormans, T. P. J., Draisma, A., Drogt, I., Eikemans, B. J. W., Elbers, P. W. G., Epker, J. L., Erkamp, M. L., Festen-Spanjer, B., Frenzel, T., Georgieva, L., Gritters, N. C., Hené, I. Z., Hoeksema, M., Holtkamp, J. W. M., Hoogendoorn, M. E., Jacobs, C. J. G. M., Janssen, I. T. A., Kieft, H., Koetsier, M. P., Koning, T. J. J., Kreeftenberg, H., Kusadasi, N., Lens, J. A., Lutisan, J. G., Mehagnoul-Schipper, D. J., Moolenaar, D., Nooteboom, F., Postma, N., Pruijsten, R. V., Ramnarain, D., Reidinga, A. C., Rengers, E., Rijkeboer, A. A., Rijpstra, T., Rozendaal, F. W., Schnabel, R. M., Silderhuis, V. M., Spijkstra, J. J., Spronk, P. E., te Velde, L. F., Urlings-Strop, L. C., van den Berg, A. E., van den Berg, R., van der Horst, I. C. C., van Driel, E. M., van Gulik, L., van Iersel, F. M., van Lieshout, M., van Oers, J. A. H., van Slobbe-Bijlsma, E. R., van Tellingen, M., Vandeputte, J., Verbiest, D. P., Versluis, D. J., Verweij, E., Vrolijk-de Mos, M., and Wesselink, R. M. J.

Published
2023
Full Text
View/download PDF

15. Adjuvant treatment for melanoma in clinical practice – Trial versus reality

Author

de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., and Wouters, Michel W.J.M.

Published
2021
Full Text
View/download PDF

16. Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET): an international, multicentre, retrospective, observational cohort study

Author

Agnoletto, LA, Aleman, J, Andreassi, S, Andrews, LM, Ashfield, L, Bell, H, Bengaard, AKB, Berlinghini, SB, Bini, KB, Bisoffi, ZB, Blum, KB, Boemaars, E, Boni, GB, Bosch, TM, Bosma, BE, Boutkourt, F, Bufarini, C, Bulsink, A, Cabuk, RC, Callens, GC, Candela, MC, Canonici, MC, Capone, EC, Carmo, IC, Caruso, FC, Chessa, PC, Cohet, GC, Cornelissen-Wesseling, I, Crommentuijn, KML, de Stoppelaar, FM, de Wit, HAJM, Deben, DS, Derijks, LJJ, Di Carlo, MDC, Diepstraten, J, Dilek, B, Duchek-Mann, DMK, Ebbens, MM, Ellerbroek, LJ, Ezinga, M, Falcao, MF, Falcao, FF, Fantini, LF, Farinha, HF, Filius, PMG, Fitzhugh, NJ, Fleming, G, Forsthuber, TF, Gambarelli, GG, Gambera, MG, García Yubero, CGY, Getrouw, Z, Ghazarian, CN, Goodfellow, N, Gorgas, MQG, Grinta, RG, Guda, K, Haider, DH, Hanley, J, Heitzeneder, KH, Hemminga, WL, Hendriksen, LC, Hilarius, DL, Hogenhuis, FEF, Hoogendoorn-de Graaf, IC, Houlind, MBH, Huebler, MAH, Hurkens, KPGM, Janssen, PKC, Jong, E, Kappers, MHW, Keijzers, KFM, Kemogni, MK, Kemper, EM, Kranenburg, RA, Krens, LL, Le Grand, JL G, Liang, J, Lim, S, Lindner, NL, Loche, EL, Lubich, AL, Maat, B, Maesano, CM, Maiworm, AM, Maragna, M, Marchesini, FM, Martignoni, IM, Martini, G M, Masini, CM, Mc Menamin, R, Mendes, DM, Miarons, M, Moorlag, R, Müller, MR, Nagele, FN, Nemec, KN, Oka, GO, Otten-Helmers, AG, Pagliarino, SP, Pappalardo, FP, Patel, M, Peverini, PM, Pieraccini, FP, Platania, EMP, Pons-Kerjean, NPK, Portillo Horcajada, LPH, Rametta, GR, Rijo, JR, Roelofsen, EE, Roobol-Meuwese, E, Rossi, LR, Russel, SAH, Safipour, Z, Salaffi, FS, Saleh, L, Schimizzi, AMS, Schols, JMGA, Schwap, MS, Scott, MG, Slijfer, EAM, Slob, EMA, Soares, JS, Solano, MS, Sombogaard, F, Stemer, GS, Tardella, MT, ter Horst, PGJ, Tessari, RT, Tournoy, J, van den Berg, RB, Van der Linden, L, van der Linden, PD, van Dijk, SC, Van Etten, RW, van Haelst, IMM, van Heuckelum, M, van Kan, HJM, van Nieuwkoop, C, van Onzenoort, HAW, van Wijngaarden, P, Verdonk, JDJ, Verri, Fv, Verstijnen, JAMC, Veyrier, MV, Viegas, EV, Visser, LE, Vos, A, Vromen, MAM, Wierenga, PC, Wong, DR, Zenico, CZ, Zuppini, TZ, Sablerolles, Roos S G, Lafeber, Melvin, van Kempen, Janneke A L, van de Loo, Bob P A, Boersma, Eric, Rietdijk, Wim J R, Polinder-Bos, Harmke A, Mooijaart, Simon P, van der Kuy, Hugo, Versmissen, Jorie, and Faes, Miriam C

Published
2021
Full Text
View/download PDF

17. Functional outcomes in symptomatic versus asymptomatic patients undergoing incisional hernia repair: Replacing one problem with another? A prospective cohort study in 1312 patients

Author

Abet, E., Ain, J.-F., Arnalsteen, L., Baraket, O., Beck, M., Bellouard, A., Benizri, E., Berney, C., Bilem, D., Binot, D., Blanc, B., Blazquez, D., Bonan, A., Boukortt, T., Brehant, O., Cas, O., Champault-Fezais, A., Chau, A., Chollet, J.-M., Constantin, M., Cossa, J.-P., Dabrowski, A., David, A., Demaret, S., Dubuisson, V., Dugue, T., El Nakadi, I., Faure, J.-P., Frileux, P., Fromont, G., Gadiri, N., Gillion, J.-F., Glehen, O., Hennequin, S., Isambert, M., Jurczak, F., Khalil, H., Lamblin, A., Largenton, C., Lavy, M., Lepère, M., Le Toux, N., Magne, E., Manfredelli, S., Mariette, C., Marion, Y., Mercoli, H.-A., Mesli Smain, N., Moszkowicz, D., Najim, M., Oberlin, O., Odet, E., Ortega Deballon, P., Pavis d’Escurac, X., Pichot Delahaye, V., Putinier, J.B., Regimbeau, J.M., Renard, Y., Romain, B., Rouquie, D., Soler, M., Soufron, J., Roos, S., Thillois, J.-M., Tiry, P., Vauchaussade De Chaumont, A., Vinatier, E., Vu, P., Verhaeghe, R., Zaranis, C., Zeineb, M., de Smet, Gijs H.J., Sneiders, Dimitri, Yurtkap, Yagmur, Menon, Anand G., Jeekel, Johannes, Kleinrensink, Gert-Jan, Lange, Johan F., and Gillion, Jean-François

Published
2020
Full Text
View/download PDF

18. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2021
Full Text
View/download PDF

22. External Validation of the European Hernia Society Classification for Postoperative Complications after Incisional Hernia Repair: A Cohort Study of 2,191 Patients

Author

Ain, J.-F., Beck, M., Barrat, C., Berney, C., Berrod, J.-L., Binot, D., Boudet, M.-J., Bousquet, J., Blazquez, D., Bonan, A., Cas, O., Champault-Fezais, A., Chastan, P., Cardin, J.-L., Chollet, J.-M., Cossa, J.-P., Dabrowski, A., Démaret, S., Drissi, F., Durou, J., Dugue, T., Faure, J.-P., Framery, D., Fromont, G., Gainant, A., Gauduchon, L., Genser, L., Gillion, J.-F., Guillaud, A., Jacquin, C., Jurczak, F., Khalil, H., Lacroix, A., Ledaguenel, P., Lepère, M., Lépront, D., Letoux, N., Loriau, J., Magne, E., Ngo, P., Oberlin, O., Paterne, D., Pavis d'Escurac, X., Potiron, L., Renard, Y., Soler, M., Rignier, P., Roos, S., Thillois, J.-M., Tiry, P., Verhaeghe, R., Vu, P., Zaranis, C., Kroese, Leonard F., Kleinrensink, Gert-Jan, Lange, Johan F., and Gillion, Jean-Francois

Published
2018
Full Text
View/download PDF

23. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2022
Full Text
View/download PDF

25. ALL-tRNAseq enables robust tRNA profiling in tissue samples

Author

Chantal Scheepbouwer, Ernesto Aparicio-Puerta, Cristina Gomez-Martin, Heleen Verschueren, Monique van Eijndhoven, Laurine E. Wedekind, Stavros Giannoukakos, Nathalie Hijmering, Lisa Gasparotto, Hilde T. van der Galien, Roos S. van Rijn, Eleonora Aronica, Robby Kibbelaar, Vivi M. Heine, Pieter Wesseling, David P. Noske, W. Peter Vandertop, Daphne de Jong, D. Michiel Pegtel, Michael Hackenberg, Tom Wurdinger, Alan Gerber, Danijela Koppers-Lalic, Pathology, AII - Inflammatory diseases, ANS - Cellular & Molecular Mechanisms, Child and Adolescent Psychiatry & Psychosocial Care, Neurosurgery, ANS - Neurovascular Disorders, ANS - Systems & Network Neuroscience, CCA - Cancer Treatment and Quality of Life, Human genetics, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Amsterdam Neuroscience - Compulsivity, Impulsivity & Attention, AII - Cancer immunology, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Amsterdam Neuroscience - Neurovascular Disorders, Amsterdam Neuroscience - Systems & Network Neuroscience, and AII - Infectious diseases

Subjects
tissue samples, Genetics, cancer, high-throughput sequencing, transfer RNA, Developmental Biology
Abstract

Transfer RNAs (tRNAs) are small adaptor RNAs essential for mRNA translation. Alterations in the cellular tRNA population can directly affect mRNA decoding rates and translational efficiency during cancer development and progression. To evaluate changes in the composition of the tRNA pool, multiple sequencing approaches have been developed to overcome reverse transcription blocks caused by the stable structures of these molecules and their numerous base modifications. However, it remains unclear whether current sequencing protocols faithfully capture tRNAs existing in cells or tissues. This is specifically challenging for clinical tissue samples that often present variable RNA qualities. For this reason, we developed ALL-tRNAseq, which combines the highly processive MarathonRT and RNA demethylation for the robust assessment of tRNA expression, together with a randomized adapter ligation strategy prior to reverse transcription to assess tRNA fragmentation levels in both cell lines and tissues. Incorporation of tRNA fragments not only informed on sample integrity but also significantly improved tRNA profiling of tissue samples. Our data showed that our profiling strategy effectively improves classification of oncogenic signatures in glioblastoma and diffuse large B-cell lymphoma tissues, particularly for samples presenting higher levels of RNA fragmentation, further highlighting the utility of ALL-tRNAseq for translational research.

Published
2023
Full Text
View/download PDF

26. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Author

Ismail, Rawa K., Sikkes, Nienke O., Wouters, Michel W.J.M., Hilarius, Doranne L., Pasmooij, Anna M.G., van den Eertwegh, Alfonsus J.M., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B.A.G., Hospers, Geke A.P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P.M., ten Tije, Bert-Jan, van der Veldt, Astrid A.M., Vreugdenhil, Art, van Dartel, Maaike, and de Boer, Anthonius

Published
2021
Full Text
View/download PDF

31. Response to immune checkpoint inhibitors in acral melanoma

Author

Olivier J. van Not, Melissa M. de Meza, Alfons J.M. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jesper van Breeschoten, Jan-Willem B. de Groot, Geke A.P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Marion A.M. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Han J. Bonenkamp, Marye J. Boers-Sonderen, Willeke A.M. Blokx, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk, Medical Oncology, Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Obstetrics and gynaecology, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
Cancer Research, Skin Neoplasms, Survival, Melanoma/mortality, THERAPY, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], SUBTYPES, Cohort Studies, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Immune checkpoint inhibitors, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Skin Neoplasms/drug therapy, Humans, Prospective Studies, Melanoma, OUTCOMES, Response, KIT, EFFICACY, Nivolumab/adverse effects, Ipilimumab, Immune Checkpoint Inhibitors/therapeutic use, MUCOSAL, Nivolumab, Oncology, ARM, Immunotherapy, Ipilimumab/therapeutic use
Abstract

Background: Recent reports suggest the limited efficacy of immune checkpoints inhibitors in advanced acral melanoma (AM). This study aims to investigate the clinical outcomes of immune checkpoint inhibitors in patients with stage III and IV AM and compare them to cutaneous melanoma (CM). Methods: We included patients with advanced AM and CM treated with first-line anti -programmed cell death (PD)-1 monotherapy or ipilimumab-nivolumab registered in the prospective nationwide Dutch Melanoma Treatment Registry. Objective response rates, progression free survival (PFS) and overall survival (OS) were calculated. A Cox proportional hazard model was used to assess the prognostic factors with PFS and OS. Results: In total, 2058 patients (88 AM and 1970 CM) with advanced melanoma were included. First-line objective response rates were 34% for AM versus 54% for CM in the advanced anti-PD-1 cohort and 33% for AM versus 53% for CM in the advanced ipilimumab-nivolumab cohort. The Median PFS was significantly shorter for anti-PD-1 treated AM patients (3.1 months; 95%CI: 2.8-5.6) than patients with CM (10.1 months; 95%CI: 8.5-12.2) (P < 0.001). In patients with advanced melanoma, AM was significantly associated with a higher risk of progression (HRadj 1.63; 95%CI: 1.26-2.11 ; P < 0.001) and death (HRadj 1.54; 95%CI: 1.15-2.06; P Z 0.004) than CM. Conclusions: This study shows lower effectiveness of anti-PD-1 monotherapy and ipilimumab-nivolumab in AM, with lower response rates, PFS and OS than CM. This group of patients should be prioritised in the development of alternative treatment strategies. 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Published
2022
Full Text
View/download PDF

32. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., ten Tije, Bert-Jan J., van der Veldt, Astrid A. M., Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2021
Full Text
View/download PDF

39. No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study

Author

Sablerolles, Roos S. G., Hogenhuis, Freija E. F., Lafeber, Melvin, Loo, Bob P. A., Borgsteede, Sander D., Boersma, Eric, Versmissen, Jorie, Kuy, Hugo, Internal Medicine, Pharmacy, and Cardiology

Subjects
medicine.medical_specialty, Angiotensin-Converting Enzyme Inhibitors, angiotensin‐converting enzyme inhibitor, 030226 pharmacology & pharmacy, SARS‐CoV‐2, law.invention, Angiotensin Receptor Antagonists, 03 medical and health sciences, 0302 clinical medicine, COVID‐19, law, Internal medicine, Clinical endpoint, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Retrospective Studies, Pharmacology, biology, SARS-CoV-2, business.industry, Incidence (epidemiology), COVID-19, Angiotensin-converting enzyme, Original Articles, Emergency department, Odds ratio, mortality, Intensive care unit, Hospitals, Confidence interval, angiotensin II receptor blocker, Hypertension, biology.protein, Original Article, Observational study, business
Abstract

Since the outbreak of SARS-CoV-2, also known as COVID-19, conflicting theories have circulated on the influence of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) on incidence and clinical course of COVID-19, but data are scarce. The COvid MEdicaTion (COMET) study is an observational, multinational study that focused on the clinical course of COVID-19 (i.e. hospital mortality and intensive care unit [ICU] admission), and included COVID-19 patients who were registered at the emergency department or admitted to clinical wards of 63 participating hospitals. Pharmacists, clinical pharmacologists or treating physicians collected data on medication prescribed prior to admission. The association between the medication and composite clinical endpoint, including mortality and ICU admission, was analysed by multivariable logistic regression models to adjust for potential confounders. A total of 4870 patients were enrolled. ACEi were used by 847 (17.4%) patients and ARB by 761 (15.6%) patients. No significant association was seen with ACEi and the composite endpoint (adjusted odds ratio [OR] 0.94; 95% confidence interval [CI] 0.79 to 1.12), mortality (OR 1.03; 95%CI 0.84 to 1.27) or ICU admission (OR 0.96; 95%CI 0.78 to 1.19) after adjustment for covariates. Similarly, no association was observed between ARB and the composite endpoint (OR 1.09; 95%CI 0.90 to 1.30), mortality (OR 1.12; OR 0.90 to 1.39) or ICU admission (OR 1.21; 95%CI 0.98 to 1.49). In conclusion, we found no evidence of a harmful or beneficial effect of ACEi or ARB use prior to hospital admission on ICU admission or hospital mortality.

Published
2021

40. Laparoscopic ventral hernia repair using a novel intraperitoneal lightweight mesh coated with hyaluronic acid: 1-year follow-up from a case–control study using the Hernia-Club registry

Author

Gillion, J.-F., Fromont, G., Lepère, M., Letoux, N., Dabrowski, A., Zaranis, C., Barrat, C., Ain, J.-F., Beck, M., Berney, C., Berrot, J.-L., Binot, D., Blazquez, D., Bonan, A., Cas, O., Champault-Fezais, A., Chastan, P., Cardin, J.-L., Chollet, J.-M., Cossa, J.-P., Durou, J., Dugue, T., Framery, D., Faure, J.-P., Gainant, A., Gauduchon, L., Jacquin, C., Jurczak, F., Khalil, H., Lacroix, A., Ledaguenel, P., Loriau, J., Magne, E., Ngo, P., Paterne, D., Pavisd’Escurac, X., Renard, Y., Soler, M., Rignier, P., Roos, S., Thillois, J.-M., Tiry, P., and The Hernia-Club Members

Published
2016
Full Text
View/download PDF

41. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

Alfonsus J. M. van den Eertwegh, Michel W.J.M. Wouters, Roos S. van Rijn, John B. A. G. Haanen, Maureen J.B. Aarts, Bert-Jan J. ten Tije, Karijn P M Suijkerbuijk, Christian U. Blank, Jesper van Breeschoten, Geke A. P. Hospers, Jan-Willem B de Groot, Franchette W P J van den Berkmortel, Ellen Kapiteijn, Doranne L. Hilarius, Marye J Boers-Sonderen, Djura Piersma, Art Vreugdenhil, Astrid A M van der Veldt, Willeke A. M. Blokx, VU University medical center, Obstetrics and gynaecology, Internal medicine, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Radiology & Nuclear Medicine, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Medische Oncologie (9)

Subjects
Oncology, Cancer Research, medicine.medical_specialty, PHASE-3, First line, Systemic therapy, VEMURAFENIB, Article, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], POOLED ANALYSIS, Matched cohort, SDG 3 - Good Health and Well-being, Internal medicine, Medicine, METASTATIC MELANOMA, neoplasms, Melanoma, Survival analysis, Advanced melanoma, nivolumab, business.industry, IPILIMUMAB, Anti pd 1, medicine.disease, DABRAFENIB, Propensity score matching, pembrolizumab, business
Abstract

Contains fulltext : 232046.pdf (Publisher’s version ) (Closed access) BACKGROUND: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAF(V600)-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAF(V600)-mutant melanoma patients. METHODS: We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAF(V600)-mutation treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method. RESULTS: Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95% CI: 37.3-NE) vs. 19.8 months (95% CI: 16.7-24.3) and 65.4% (95% CI: 58.1-73.6) vs. 41.7% (95% CI: 34.2-51.0). CONCLUSIONS: Our data suggest that in the matched BRAF(V600)-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics.

Published
2021
Full Text
View/download PDF

42. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

Djura Piersma, Marye J Boers-Sonderen, Geke A. P. Hospers, Karijn P M Suijkerbuijk, Christian U. Blank, Roos S. van Rijn, Astrid A M van der Veldt, Jan-Willem B de Groot, Ellen Kapiteijn, Franchette W P J van den Berkmortel, Alfonsus J. M. van den Eertwegh, Jesper van Breeschoten, Doranne L. Hilarius, Bert-Jan J. ten Tije, Michel W.J.M. Wouters, Art Vreugdenhil, John B. A. G. Haanen, Maureen J.B. Aarts, and Willeke A. M. Blokx

Subjects
Oncology, medicine.medical_specialty, Cancer Research, business.industry, First line, Anti pd 1, Mutant, Correction, Cancer, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, business, Survival analysis, Advanced melanoma
Abstract

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1

Published
2022
Full Text
View/download PDF

43. Correction:First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (British Journal of Cancer, (2021), 124, 7, (1222-1230), 10.1038/s41416-020-01229-1)

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., Tije, Bert-Jan J. ten, Veldt, Astrid A. M. van der, Vreugdenhil, Art, Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M., Internal medicine, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Medical oncology, AII - Cancer immunology, CCA - Cancer biology and immunology, and CCA - Cancer Treatment and quality of life

Abstract

The original version of this article unfortunately contained a mistake. During online publication of this article an incorrect notification was included by the Publisher in the Additional Information. The notification incorrectly stated that the licence terms for these articles would switch to a Creative Commons Attribution 4.0 International (CC BY 4.0) after a period of 12 months. This notification has been removed and the articles have been updated.

Published
2022
Full Text
View/download PDF

48. Association between Clinical Frailty Scale and mortality 24 months after hospitalisation in adult patients with COVID-19

Author

Julia Minnema, Melvin Lafeber, Roos S.G. Sablerolles, Janneke A.L. van Kempen, Lisanne Tap, Harmke A. Polinder-Bos, Bob P.A. van de Loo, Hugo van der Kuy, Miriam C. Faes, Jacomien Aleman, Jos Tournoy, Lorenz Van der Linden, Marco Gambera, Isabella Martignoni, Ronald Van Etten, Hein van Onzenoort, Mariette Kappers, Peter van Wijngaarden, Jose Verstijnen, Vera Theeuwes, Marleen Kemper, Elise Slob, Ferdi Sombogaard, Heshu Abdullah-Koolmees, Roland van den Berg, Hugo de Wit, Betul Dilek, Freija Hogenhuis, Vahid Buyukayten, Britt te Brake, Margriet Nieuwenhuijzen, Maria Scheeren, Madelief de Wit, Arjan Bulsink, Ingrid van Haelst, Peter ter Horst, Rosalie Moorlag, Anja Vos, Annemiek Otten-Helmers, Erik van Kan, Marije Voskamp, Marieke Ebbens, Marieke Ezinga, Cees van Nieuwkoop, Loes Visser, Caroline Ghazarian, Doranne Hilarius, Gonneke Hermanides, Carlinda Bresser, Judith Derijks-Engwegen, Ebbie Boemaars, Zahira Getrouw, Barbara Maat, Peter Wierenga, Tessa Bosch, Lisanne Krens, Kajie Liang, Langeza Saleh, Milou van Heuckelum, Linda Hendriksen, Paul van der Linden, Kaylen Guda, Kristel Crommentuijn, Ilse Cornelissen-Wesseling, Jeroen Diepstraten, Jacobien Ellerbroek, Saskia Coenradie, Debbie Deben, Kim Hurkens, Dennis Wong, Marion Vromen, Marjolein de Bock, Suzan Savelkoul, Saskia Wolters, Louise Andrews, Eefje Jong, Rosanne Kranenburg, Joana Soares, Fatima Falcao, Mariana Solano, Erica Viegas, Margarida Falcao, Helena Farinha, Dina Mendes, Joao Rijo, Marta Miarons, Maria Queralt Gorgas, Cristina García Yubero, Laura Portillo Horcajada, Kim Keijzers, Silke Lim, Linden Ashfield, Helen Bell, Naomi Fitzhugh, Glenda Fleming, Nicola Goodfellow, Joanne Hanley, Michael Scott, Simon P. Mooijaart, Jacobijn Gussekloo, Petra Elders, and Geeske Peeters

Subjects
Frailty, COVID-19, Long-term, Survival, Science (General), Q1-390, Social sciences (General), H1-99
Abstract

Background: The clinical frailty scale (CFS) was used as a triage tool for medical decision making during the COVID-19 pandemic. The CFS has been posed as a suitable risk marker for in-hospital mortality in COVID-19 patients. We evaluated whether the CFS is associated with mortality 24 months after hospitalisation for COVID-19. Methods: The COvid MEdicaTion (COMET) study is an international, multicentre, observational cohort study, including adult patients hospitalised for COVID-19 between March 2020–July 2020. Patients’ characteristics, prescribed medication, clinical characteristics, and CFS were collected at admission, survival data were collected 24 months after hospitalisation. Multivariable cox proportional hazard models stratified by age (

Published
2024
Full Text
View/download PDF

50. Serum Calcification Propensity and the Risk of Cardiovascular and All-Cause Mortality in the General Population

Author

Stephan J. L. Bakker, Parisa Aghagolzadeh, Martin H. de Borst, Marc G. Vervloet, Jan-Luuk Hillebrands, Harry van Goor, Ron T. Gansevoort, Matthias Bachtler, Anne-Roos S. Frenay, Coby Eelderink, Andreas Pasch, Charlotte A Te Velde-Keyzer, Peter R van Dijk, Emma A. Vermeulen, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Groningen Institute for Organ Transplantation (GIOT), and Lifestyle Medicine (LM)

Subjects
Adult, Male, Risk, medicine.medical_specialty, Population, 030232 urology & nephrology, Disease, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Internal medicine, Cause of Death, medicine, Humans, Prospective Studies, education, Vascular Calcification, Vascular calcification, Aged, Proportional Hazards Models, education.field_of_study, business.industry, Middle Aged, medicine.disease, Cardiovascular Diseases, Cardiology, Kidney Failure, Chronic, Female, Cardiology and Cardiovascular Medicine, business, All cause mortality, Calcification
Abstract

Objective: Vascular calcification contributes to the cause of cardiovascular disease. The calciprotein particle maturation time (T 50 ) in serum, a measure of calcification propensity, has been linked with adverse outcomes in patients with chronic kidney disease, but its role in the general population is unclear. We investigated whether serum T 50 is associated with cardiovascular mortality in a large general population-based cohort. Approach and Results: The relationship between serum T 50 and cardiovascular mortality was studied in 6231 participants of the PREVEND (Prevention of Renal and Vascular End-Stage Disease) cohort. All-cause mortality was the secondary outcome. Mean (±SD) age was 53±12 years, 50% were male, and mean serum T 50 was 329±58 minutes. A shorter serum T 50 is indicative of a higher calcification propensity. Serum T 50 was inversely associated with circulating phosphate, age, estimated glomerular filtration rate, and alcohol consumption, whereas plasma magnesium was positively associated with serum T 50 ( P R 2 =0.281). During median (interquartile range) follow-up for 8.3 (7.8–8.9) years, 364 patients died (5.8%), of whom 95 (26.1%) died from a cardiovascular cause. In multivariable Cox proportional hazard models, each 60 minutes decrease in serum T 50 was independently associated with a higher risk of cardiovascular mortality (fully adjusted hazard ratio [95% CI], 1.22 [1.04–1.36], P =0.021). This association was modified by diabetes mellitus; stratified analysis indicated a more pronounced association in individuals with diabetes mellitus. Conclusions: Serum T 50 is independently associated with an increased risk of cardiovascular mortality in the general population and thus may be an early and potentially modifiable risk marker for cardiovascular mortality.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results